• Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • Should We Screen for HCC?

Should We Screen for HCC?

Screening patients with cirrhosis for hepatocellular carcinoma (HCC) by abdominal ultrasonography (USS) and/or measurement of serum level of alpha-fetoprotein (AFP) is not associated with reduced mortality from this cancer, reseachers report from a matched case–control study in the October issue of Gastroenterology. Patients with cirrhosis have a high risk (1%–8%

Read more
  • Can Nonlytic T cells be Engineered to Fight HBV Infection?

Can Nonlytic T cells be Engineered to Fight HBV Infection?

Nonlytic T cells with receptors engineered to recognize HBV suppress virus replication in hepatocytes and limit infection of mice by activating APOBEC3, researchers report in the July issue of Gastroenterology. These cells are not hepatotoxic and might be developed for treatment of chronic HBV infection. T cells control chronic viral infections, and virus-specific

Read more
  • Developing a New Combination Treatment for HBV Infection

Developing a New Combination Treatment for HBV Infection

NVR3–778, a capsid assembly modulator, reduces serum levels of hepatitis B virus (HBV) DNA and HBV RNA in mice with humanized livers and stable HBV infection, researchers report in the February issue of Gastroenterology. The combination of NVR3–778 and interferon prevented viral replication and HBV RNA particle production to a greater extent than

Read more
  • A New Pathway for Transmitting HBV DNA?

A New Pathway for Transmitting HBV DNA?

Extracellular vesicles carry HBV DNA as cargo that can be transmitted to other hepatocytes, researchers report in the March issue of Cellular and Molecular Gastroenterology and Hepatology. Their findings identify an antibody-neutralization–resistant route of HBV infection. Approximately 350 million people are chronically infected by HBV worldwide, and some of these

Read more
  • How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

How Can We Study Genetic Heterogeneity Within Hepatocellular Carcinomas?

Researchers have developed a patient-derived cell line-based model to study how intratumor heterogeneity affects sensitivity of hepatocellular carcinoma (HCC) to different therapeutic agents, reported in the January issue of Gastroenterology. HCCs have a large amount of genetic heterogeneity within each tumor, making them difficult to treat. Multiple regions of tumors

Read more
  • What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • What is the Best Treatment Strategy for Hepatitis B?

What is the Best Treatment Strategy for Hepatitis B?

Response-guided interferon therapy is the most cost-effective first-line treatment for hepatitis B e antigen (HBeAg)-positive patients, whereas nucleos(t)ide analogues are the most cost-effective first-line therapy for HBeAg-negative patients, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Pegylated interferon and nucleos(t)ide analogues are recommended first-line treatment options for

Read more
  • A New Approach to Hepatitis B Therapy?

A New Approach to Hepatitis B Therapy?

Cyclophilins are involved in multiple steps of the hepatitis B virus (HBV) life cycle in hepatocytes—cyclophilin inhibitors reduce viral replication and HBV envelope protein production and secretion, researchers report in the February issue of Gastroenterology. The cyclophilin inhibitor alisporivir, combined with the HBV polymerase inhibitor, reduces markers of HBV infection

Read more